Aceneuramic acid - Nobelpharma/ Ultragenyx Pharmaceutical

Drug Profile

Aceneuramic acid - Nobelpharma/ Ultragenyx Pharmaceutical

Alternative Names: Ace-ER - Ultragenyx; Aceneuramic acid extended-release - Ultragenyx; Kepnetic; N-acetylneuraminic acid (anhydride) - Nobelpharma; NANA; Neu5Ac; NPC 09; SA-ER - Ultragenyx; Sialic acid; Sialic acid ER - Ultragenyx; Sialic acid extended release - Ultragenyx; UX 001 Sialic acid; UX-001; UX-001 SA-ER

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nobelpharma
  • Developer Hadassah Medical Organization; Japan Agency for Medical Research and Development; Nobelpharma; Tohoku University; Ultragenyx Pharmaceutical
  • Class Neuraminic acids; Sialic acids; Small molecules
  • Mechanism of Action Muscle protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Nonaka distal myopathy
  • Phase II Thrombocytopenia

Most Recent Events

  • 30 Sep 2017 Nobelpharma completes a phase II/III trial in Nonaka distal myopathy in Japan (PO) (UMIN000020683)
  • 22 Aug 2017 Top-line adverse events data from a phase III trial in Nonaka distal myopathy released by Ultragenyx Pharmaceutical
  • 22 Aug 2017 Ultragenyx Pharmaceutical plans to discontinue the development of aceneuramic acid for Nonaka distal myopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top